Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Mahale P, Nomburg J, Song JY, Steinberg M, Starrett G, Boland J, et al. Metagenomic analysis to identify novel infectious agents in systemic anaplastic large cell lymphoma. Infect Agent Cancer. 2021;16(1):65.

Kasashima H, Duran A, Martinez-Ordoñez A, Nakanishi Y, Kinoshita H, Linares JF, et al. Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast Population. Dev Cell. 2021;56(1):95-110.e10.

Mavragani CP, Kirou KA, Nezos A, Seshan S, Wild T, Wahl SM, et al. Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. Clin Immunol. 2021;223:108649.

Cervera-Hernandez ME, Ikemura K, McCort ME. Cytomegalovirus skin disease in a kidney transplant patient. BMJ Case Rep. 2021;14(7).

Gómez-Escobar LG, Hoffman KL, Choi JJ, Borczuk A, Salvatore S, Alvarez-Mulett SL, et al. Cytokine signatures of end organ injury in COVID-19. Sci Rep. 2021;11(1):12606.

Gaffney C, Liu D, Cooley V, Ma X, Angulo C, Robinson B, et al. Tumor size and genomic risk in localized prostate cancer. Urol Oncol. 2021;39(7):434.e17-434.e22.

Humtsoe JO, Kim H-, Leonard B, Ling S, Keam B, Marchionni L, et al. Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. Cancer Res. 2021;81(4):1001-1013.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo M-, Avcin T, Bertolaccini ML, et al. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res (Hoboken). 2021;73(10):1490-1501.

Sparano JA, Lee JY, Kaplan LD, Ramos JC, Ambinder RF, Wachsman W, et al. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. Haematologica. 2021;106(3):730-735.

Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2(4):444-456.